Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

pharmatheway 7 posts  |  Last Activity: Jun 13, 2016 11:43 AM Member since: May 4, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Unexpected Reaction to the Positive News.

    by ed36bat Jun 13, 2016 11:27 AM
    pharmatheway pharmatheway Jun 13, 2016 11:43 AM Flag

    Stupid selling imo I do believe this will get approved within a 8 months .Folks forget that this trial has SPA from the FDA..

    Sentiment: Strong Buy

  • pharmatheway pharmatheway May 10, 2016 3:01 PM Flag

    Still holding original position.

    Sentiment: Strong Buy

  • Reply to

    Traders are so powerful

    by hufrd Apr 18, 2016 12:32 PM
    pharmatheway pharmatheway Apr 20, 2016 11:09 AM Flag

    Nothing funny about fighting RCC it's a killer .My brother lost his battle last year August 13 He was i a good clinical trial with (Nivolumab) _- OPDIVO It gave him 2 years thats it ,so my hope is that something like this my work for others .I believe this is a good bet on Nobel Prize winner, Dr. Ralph Steinman. this Company's co-founder..I gambled with PCYC and won so i am playing with the house money.. P.S. I also own BMY,ABBV,and TGTX JMO

    Sentiment: Strong Buy

  • Reply to

    Traders are so powerful

    by hufrd Apr 18, 2016 12:32 PM
    pharmatheway pharmatheway Apr 19, 2016 5:58 PM Flag

    In the multicenter Phase 2 trial led by Dr. Asim Amin, medical oncologist at the Levine Cancer Institute, encouraging median overall survival of 30.2 months was observed for all patients treated with the combination of AGS-003 plus sunitinib. According to the International mRCC Database Consortium, similar unfavorable risk mRCC patients have an expected overall survival of 14.7 months. In addition, in the Phase 2 trial, patients with intermediate risk experienced a median survival in excess of 5 years.

  • Reply to

    Traders are so powerful

    by hufrd Apr 18, 2016 12:32 PM
    pharmatheway pharmatheway Apr 19, 2016 12:41 PM Flag

    SPA is nothing? I stayed with PCYC after it received SPA from the FDA and i think it did rather well wouldn't you say? Also we had many nay sayers such as yourself.

    Sentiment: Strong Buy

  • Reply to

    Traders are so powerful

    by hufrd Apr 18, 2016 12:32 PM
    pharmatheway pharmatheway Apr 18, 2016 1:06 PM Flag

    You are so wrong they have SPA in a phase 3 trial for RCC .Nothing like DNDN .Please do some research before you post.

    Sentiment: Strong Buy

  • Recently approved drugs such as Yervoy and Opdivo from Bristol Myers Squibb Co and Merck & Co Inc's Keytruda have helped some patients sustain remission. But those first-generation therapies do not work for everyone, and scientists are trying to understand how to make them more effective.

    "Very little progress has been made over the last several decades," Parker said, referring to cancer drug research. "Average life expectancy has only increased three to six months with some of these drugs that cost billions to develop."

    THREE KEY RESEARCH AREAS

    The institute has identified three key areas of research - modifying a patient's own immune system T-cells to target a tumor; studying ways to boost patient response to current immunotherapy drugs; and research to identify other novel targets to attack a tumor.

    Sentiment: Strong Buy

SNTA
0.2948+0.0346(+13.30%)4:00 PMEDT